Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438641 · ClinicalTrials.gov registry record
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 30
- Enrollment target
NCT05438641: Completed study, sponsored by Stanford University.
NCT05438641 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05438641 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when admitted to medical/surgical units. During the last 15 months, the investigators have implemented a benzodiazepine-sparing management approach with very positive clinical outcomes. The BZDP-sparing protocol consists of a combination of alpha-2 agonist and/or anticonvulsant agents; all currently being used for the management of other medical conditions. This project intends to collect and analyze the data of all subjects managed with this approach to better understand its effectiveness and assess for potential adverse effects.
Primary Outcome
The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) measure is a ten item measure of alcohol withdrawal symptoms. The CIWA total score is the summation of 10 questions, with a range from 0 (little to no withdrawal) to 67 (worse alcohol withdrawal).
Interventions
- DRUG BZDP-Sparing Protocol
- DRUG BZDP-Based Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-08 |
What the finished NCT05438641 record still lists
NCT05438641 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which BZDP-Sparing Protocol is the first listed.
NCT05438641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05438641 about?
NCT05438641 is a clinical study titled "Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants". Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when admitted to medical/surgical units. During the last 15 months, the inve...
What is the current status of trial NCT05438641?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT05438641?
The interventions under investigation include: BZDP-Sparing Protocol (DRUG), BZDP-Based Protocol (DRUG).
Who is sponsoring clinical trial NCT05438641?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia